Drug intelligence / Profile preview

111in-ipn01087

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous

Overview

111In-IPN01087 is a radiopharmaceutical diagnostic agent consisting of the neurotensin receptor type 1 (NTSR1) antagonist, IPN01087, labeled with the radioisotope indium-111. It was developed for use as an imaging agent in patients with cancers that overexpress NTSR1, such as colorectal cancer and pancreatic ductal adenocarcinoma. The drug is administered intravenously and used in conjunction with single-photon emission computed tomography (SPECT) to visualize tumors expressing NTSR1. Its mechanism of action involves selective binding to NTSR1 on tumor cells, enabling targeted imaging through radionuclide detection[1][2][3]. The development of this agent was discontinued after phase 1 clinical trials.

Other names: indium In 111 IPN01087

Targets

NTR1 (Nitroreductase-1)

Beyond the preview

Go deeper on 111in-ipn01087.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 111in-ipn01087.

Explore the full profile